Recent reports have shown that high expression of ITM2A is associated with poor prognosis in ovarian cancer,[25] and TIMD4 might provide a novel strategy for improving the clinical efficacy of cancer immunotherapy.[26] Thus, our data not only confirm that previously identified genes are associated with exhausted T cells but also identify potential biomarkers for diagnosis and immunotherapy. This evidence concerns the gene ITM2A and ovarian cancer.